Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatmentsAlfonso Cortés, Alfredo Carrato, José L. Casado et al.|European Journal of Cancer|2022Cited by 30
1022P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)Jonathan W. Riess, V. Villaflor, J. Rubio Perez et al.|Annals of Oncology|2024Cited by 3